VJHemOnc is committed to improving our service to you

ASH 2019 | Lymphoma updates: CAR-T, brentuximab & nivolumab

VJHemOnc is committed to improving our service to you

Nathan Fowler

Nathan Fowler, MD, University of Texas MD Anderson Cancer Center, Houston, TX, highlights key lymphoma news from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. These include updates on JCAR017 in non-Hodgkin lymphoma, and the combination of bretuximab vedotin and the checkpoint inhibitor nivolumab in Hodgkin lymphoma.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter